AOD-9604 vs Compounded Semaglutide
A side-by-side research comparison of AOD-9604 and Compounded Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | AOD-9604 | Compounded Semaglutide |
|---|---|---|
| Full name | Advanced Obesity Drug Fragment 176-191 (Modified) | Compounded Semaglutide (503B Pharmacy) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Compounded medication |
| Mechanism | Mimics the lipolytic domain of growth hormone (hGH 176-191), stimulating fat oxidation and inhibiting de novo lipogenesis through pathways independent of IGF-1 and growth signaling. | Identical to branded semaglutide - a GLP-1 receptor agonist with a fatty acid chain for albumin binding, providing extended half-life. Reduces appetite, slows gastric emptying, and improves insulin sensitivity. |
| Molecular weight | 1815.08 Da | 4113.58 Da |
| Half-life | ~2-3 hours | ~7 days |
| Bioavailability | ~90% subcutaneous | ~89% subcutaneous |
| Typical dose | 300 mcg | 0.25-2.4 mg |
| Frequency | Daily (morning, fasted) | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
AOD-9604 reported benefits
- Fat loss without muscle wasting
- No effect on blood sugar
- Cartilage repair properties
- No HGH-related side effects
Compounded Semaglutide reported benefits
- Significant weight loss (15-20%)
- Appetite suppression
- Improved glycemic control
- Cardiovascular benefits
- Reduced food noise
Related comparisons
Research and educational reference only. Not medical advice.